MIM
RYTM icon

MetLife Investment Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

MetLife Investment Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56M Buy
32,104
+3,215
+11% +$291K 0.02% 831
2026
Q1 		$2.51M Sell
28,889
-285
-1% -$27.7K 0.01% 938
2025
Q4 		$3.12M Sell
29,174
-1,188
-4% -$126K 0.02% 844
2025
Q3 		$3.07M Sell
30,362
-2,033
-6% -$189K 0.01% 877
2025
Q2 		$2.05M Sell
32,395
-19
-0.1% -$1.16K 0.01% 977
2025
Q1 		$1.72M Sell
32,414
-1,084
-3% -$60.1K 0.01% 1114
2024
Q4 		$1.88M Buy
33,498
+1,846
+6% +$102K 0.01% 1080
2024
Q3 		$1.66M Hold
31,652
– – 0.01% 1122
2024
Q2 		$1.3M Buy
31,652
+4,529
+17% +$181K 0.01% 1208
2024
Q1 		$1.18M Hold
27,123
– – 0.01% 1214
2023
Q4 		$1.25M Hold
27,123
– – 0.01% 1182
2023
Q3 		$622K Hold
27,123
– – ﹤0.01% 1491
2023
Q2 		$447K Buy
+27,123
New +$490K ﹤0.01% 1769
2022
Q2 		– Sell
-24,442
Closed -$282K – 2900
2022
Q1 		$282K Buy
24,442
+9,070
+59% +$79.6K ﹤0.01% 2130
2021
Q4 		$153K Hold
15,372
– – ﹤0.01% 2214
2021
Q3 		$201K Hold
15,372
– – ﹤0.01% 2099
2021
Q2 		$301K Hold
15,372
– – ﹤0.01% 1886
2021
Q1 		$327K Hold
15,372
– – ﹤0.01% 1763
2020
Q4 		$457K Hold
15,372
– – ﹤0.01% 1530
2020
Q3 		$333K Hold
15,372
– – ﹤0.01% 1579
2020
Q2 		$343K Buy
15,372
+1,907
+14% +$37.2K ﹤0.01% 1584
2020
Q1 		$205K Hold
13,465
– – ﹤0.01% 1682
2019
Q4 		$309K Buy
13,465
+2,209
+20% +$49.1K ﹤0.01% 1727
2019
Q3 		$243K Hold
11,256
– – ﹤0.01% 1836
2019
Q2 		$248K Sell
11,256
-7,320
-39% -$185K ﹤0.01% 1904
2019
Q1 		$509K Buy
18,576
+12,384
+200% +$356K ﹤0.01% 2034
2018
Q4 		$166K Hold
6,192
– – ﹤0.01% 2006
2018
Q3 		$181K Buy
+6,192
New +$196K ﹤0.01% 2143
2018
Q1 		– Sell
-9,862
Closed -$287K – 2212
2017
Q4 		$287K Buy
+9,862
New +$261K ﹤0.01% 1735

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MetLife Investment Management's RYTM Position: Q2 2026 in Review

MetLife Investment Management increased its Rhythm Pharmaceuticals (RYTM) stake by 11% in Q2 2026, buying an estimated $291K and bringing the position to 32,104 shares worth $3.56M. The position accounts for 0.02% of the portfolio, ranked #831.

MetLife Investment Management first reported a position in RYTM in Q4 2017 and has held it in 29 quarters since. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • MetLife Investment Management held 32,104 shares of Rhythm Pharmaceuticals worth $3.56M as of Q2 2026.
  • MetLife Investment Management bought 3,215 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $291K.
  • Rhythm Pharmaceuticals made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #831 holding.
  • MetLife Investment Management first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 29 quarters since.
  • 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.